655 related articles for article (PubMed ID: 33913511)
1. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
Gottlieb AB; Merola JF; Reich K; Behrens F; Nash P; Griffiths CEM; Bao W; Pellet P; Pricop L; McInnes IB
Br J Dermatol; 2021 Dec; 185(6):1124-1134. PubMed ID: 33913511
[TBL] [Abstract][Full Text] [Related]
2. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D
Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
[TBL] [Abstract][Full Text] [Related]
5. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
6. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
Smolen JS; Mease P; Tahir H; Schulze-Koops H; de la Torre I; Li L; Hojnik M; Sapin C; Okada M; Caporali R; Gratacós J; Goupille P; Liu Leage S; Pillai S; Nash P
Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
[TBL] [Abstract][Full Text] [Related]
8. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Kokolakis G; Warren RB; Strober B; Blauvelt A; Puig L; Morita A; Gooderham M; Körber A; Vanvoorden V; Wang M; de Cuyper D; Madden C; Nunez Gomez N; Lebwohl M
Br J Dermatol; 2023 Feb; 188(3):330-340. PubMed ID: 36751950
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
Lee MG; Huang YH; Lee JH; Lee SC; Kim TG; Aw DC; Bao W; Dee CMA; Guana A; Tsai TF
J Dermatol; 2019 Sep; 46(9):752-758. PubMed ID: 31342560
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE).
Warren RB; Barker JNWB; Finlay AY; Burden AD; Kirby B; Armendariz Y; Williams R; Hatchard C; Khare S; Griffiths CEM
Br J Dermatol; 2020 Jul; 183(1):60-70. PubMed ID: 31628677
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB;
Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
[TBL] [Abstract][Full Text] [Related]
16. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.
Cai L; Li L; Cheng H; Ding Y; Biao Z; Zhang S; Geng S; Liu Q; Fang H; Song Z; Lu Y; Li S; Guo Q; Tao J; He L; Gu J; Yang Q; Han X; Gao X; Deng D; Li S; Wang Q; Zhu J; Zhang J
Adv Ther; 2022 Jan; 39(1):583-597. PubMed ID: 34816373
[TBL] [Abstract][Full Text] [Related]
19. Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.
Kokolakis G; Vadstrup K; Hansen JB; Carrascosa JM
Dermatology; 2022; 238(4):620-629. PubMed ID: 34823247
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
Warren RB; Blauvelt A; Poulin Y; Beeck S; Kelly M; Wu T; Geng Z; Paul C
Br J Dermatol; 2021 Jan; 184(1):50-59. PubMed ID: 32594522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
